USA - NASDAQ:TENX - US88032L6056 - Common Stock
The current stock price of TENX is 6.685 USD. In the past month the price increased by 4.29%. In the past year, price increased by 69.24%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 21.68 | 405.55B | ||
AMGN | AMGEN INC | 13.7 | 160.87B | ||
GILD | GILEAD SCIENCES INC | 15.87 | 152.38B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 24.61 | 106.87B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.14B | ||
REGN | REGENERON PHARMACEUTICALS | 12.67 | 61.27B | ||
ARGX | ARGENX SE - ADR | 91.6 | 51.94B | ||
INSM | INSMED INC | N/A | 35.04B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.11 | 34.76B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.28B | ||
NTRA | NATERA INC | N/A | 24.94B | ||
BIIB | BIOGEN INC | 8.93 | 20.97B |
Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company is headquartered in Chapel Hill, North Carolina and currently employs 4 full-time employees. The firm is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The firm's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The firm is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The firm has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
TENAX THERAPEUTICS INC
101 Glen Lennox Drive, Suite 300
Chapel Hill NORTH CAROLINA 27560 US
CEO: Anthony DiTonno
Employees: 4
Phone: 19198552100
The current stock price of TENX is 6.685 USD. The price decreased by -1.98% in the last trading session.
The exchange symbol of TENAX THERAPEUTICS INC is TENX and it is listed on the Nasdaq exchange.
TENX stock is listed on the Nasdaq exchange.
11 analysts have analysed TENX and the average price target is 21.42 USD. This implies a price increase of 220.42% is expected in the next year compared to the current price of 6.685. Check the TENAX THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
TENAX THERAPEUTICS INC (TENX) has a market capitalization of 30.48M USD. This makes TENX a Nano Cap stock.
TENAX THERAPEUTICS INC (TENX) currently has 4 employees.
TENAX THERAPEUTICS INC (TENX) has a support level at 6.32 and a resistance level at 7.5. Check the full technical report for a detailed analysis of TENX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TENX does not pay a dividend.
TENAX THERAPEUTICS INC (TENX) will report earnings on 2025-11-11.
TENAX THERAPEUTICS INC (TENX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.92).
The outstanding short interest for TENAX THERAPEUTICS INC (TENX) is 6.05% of its float. Check the ownership tab for more information on the TENX short interest.
ChartMill assigns a technical rating of 9 / 10 to TENX. When comparing the yearly performance of all stocks, TENX is one of the better performing stocks in the market, outperforming 90.48% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to TENX. TENX has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months TENX reported a non-GAAP Earnings per Share(EPS) of -0.92. The EPS increased by 96.22% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -29.74% | ||
ROE | -30.47% | ||
Debt/Equity | 0 |
11 analysts have analysed TENX and the average price target is 21.42 USD. This implies a price increase of 220.42% is expected in the next year compared to the current price of 6.685.